The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and ...

The Proteus Syndrome market is entering a pivotal decade, driven by increasing disease recognition, improving diagnostic techniques, development of genetic testing techniques and other innovative ...

Key factors fueling this trend include increased awareness, improved healthcare infrastructure, and enhanced diagnostic and treatment accessibility. With the prevalence of high myopia projected to ...

The Diffuse Large B-cell Lymphoma (DLBCL) market is witnessing significant growth, driven by advancements in targeted immunotherapies like CAR-T cell ...

Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation ...

Recently released research from Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape for neovascular age-related ...

Regeneron Pharmaceuticals has recently launched a Phase 2 trial, testing the waters with a potential breakthrough in melanoma ...

The global ascites market is experiencing significant growth, driven by the rising prevalence of liver diseases, cancers, and other risk factors like alcohol consumption and hepatitis infections. Key ...

More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real world impacts, among other things, can help, explains Bennett Smith.

Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...

It may be a year later than originally planned, but Regeneron Pharmaceuticals Inc. is set to commercialize Lynozyfic (linvoseltamab) in the U.S. following FDA approval for use in adults with relapsed ...